Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Belite Bio Inc BLTE

Healthcare Biotechnology
Belite Bio, Inc is a clinical-stage biopharmaceutical drug development company. The Company is focused on advancing novel therapeutics targeting retinal degenerative eye disease, such as atrophic age-related macular degeneration (AMD), and autosomal recessive Stargardt disease type 1 (STGD) both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic... see more

Recent & Breaking News (NDAQ:BLTE)

Belite Bio Reports First-Quarter 2023 Operational Highlights and Financial Results

GlobeNewswire May 10, 2023

Belite Bio to Host Webcast on May 11, 2023 to Discuss First Quarter 2023 Financial Results

GlobeNewswire May 10, 2023

Belite Bio to Host Key Opinion Leader Webinar Discussing Progression of Childhood-onset STGD1 and Relevance of the Tinlarebant 18-month Phase 2 Data

GlobeNewswire May 4, 2023

Belite Bio Presented 18-Month Interim Data from a 24-Month Phase 2 Study of Tinlarebant in Adolescent Stargardt Disease at the 2023 ARVO Meeting

GlobeNewswire April 25, 2023

Belite Bio to Host Key Opinion Leader Webinar on RBP4 Antagonist Tinlarebant in Late-Stage Development for Stargardt Disease 1

GlobeNewswire April 11, 2023

Belite Bio Reports Full-Year 2022 Operational Highlights and Financial Results

GlobeNewswire March 31, 2023

Belite Bio to Host Webcast on April 3, 2023 to Discuss 2022 Full Year Financial Results

GlobeNewswire March 31, 2023

Belite Bio Finalizes Phase 3 Clinical Trial Plans for Advanced Dry AMD Treatment with Tinlarebant (LBS-008)

GlobeNewswire November 18, 2022

Belite Bio to Host Key Opinion Leader Webinar on October 27, 2022 to discuss LBS-008 Interim Data

GlobeNewswire October 20, 2022

Belite Bio Presented 12-Month Interim Results of LBS-008 Phase 1b/2 Study in Adolescent Stargardt Disease at AAO Annual Meeting 2022

GlobeNewswire October 1, 2022

Belite Bio Announces Late-Breaking Presentation at the American Academy of Ophthalmology 2022 Annual Meeting

GlobeNewswire September 23, 2022

Belite Bio Receives Approval of LBS-008 Phase 3 Clinical Trial in China

GlobeNewswire September 16, 2022

Belite Bio Initiates Pivotal Phase 3 Clinical Trial of LBS-008 in Stargardt Disease in the U.S.

GlobeNewswire August 22, 2022

Belite Bio Reports First Half 2022 Operational Highlights and Financial Results

GlobeNewswire August 10, 2022

Belite Bio to Host Conference Call on August 11, 2022 to Discuss First Half 2022 Financial Results

GlobeNewswire August 1, 2022

Belite Bio Submits Investigational New Drug (IND) Application to FDA for Approval to Proceed with LBS-008 Phase 3 Clinical Trial for the Treatment of Stargardt Disease

GlobeNewswire July 19, 2022

Belite Bio Announces Partial Exercise of Over-Allotment Option in Initial Public Offering

GlobeNewswire May 12, 2022

Belite Bio Presented Interim Results of LBS-008 Phase 1b/2 Study in Adolescent STGD1 at ARVO Annual Meeting 2022

GlobeNewswire May 5, 2022

Belite Bio Announces Closing of $36 Million Initial Public Offering

GlobeNewswire May 3, 2022

Belite Bio Receives FDA Fast Track Designation For LBS-008

GlobeNewswire May 3, 2022